Increases in BCL2L1 and ID1 dosage synergistically drive fate bias and competitive advantage in human pluripotent stem cells
Yingnan Lei, Nuša Krivec, Arkajyoti Sarkar, Mai Chi Duong, Anfien Huyghebaert, Charlotte Janssens, Stefaan Verhulst, Leo A. van Grunsven, Diana Al Delbany, Claudia Spits
This study shows that increased BCL2L1 and ID1 gene dosage in human pluripotent stem cells drives competitive advantage and fate bias toward non-neural ectodermal and extraembryonic fates during differentiation.
bioRxiv · Mar 29, 2026 · PreprintDevelopmental Biology